What Rogosin Institute does

The Rogosin Institute is a 501(c)(3) not-for-profit medical treatment and research institution founded in 1983 and headquartered in New York City. It operates as the largest not-for-profit kidney failure dialysis provider in the United States, running eleven dialysis centers across the New York metropolitan area and delivering the full continuum of kidney care from diagnosis through transplantation. Core services include in-center hemodialysis, home hemodialysis (including nocturnal home programs), peritoneal dialysis (CAPD/CCPD), kidney transplant evaluation with donor compatibility testing, the multidisciplinary PEAK program for advanced chronic kidney disease, the Susan R. Knafel Polycystic Kidney Disease Center, and the Comprehensive Lipid Control Center. Its primary customer segments are patients with chronic kidney disease, end-stage renal disease, transplant candidates and recipients, and referring nephrologists and primary care physicians; secondary clients include pharmaceutical sponsors and medical device manufacturers using Rogosin as a clinical trial site. Patient testimonials emphasize long-tenure relationships (2005, multi-year home dialysis), indicating high retention in chronic-care populations.

The underlying technology stack blends clinical care delivery with research infrastructure. Operationally, Rogosin maintains the Immunogenetics and Transplantation Laboratory (HLA typing and crossmatching), Home Dialysis training programs, and an 11-center regional dialysis network. In research, the Kidney Regenerative Medicine Laboratory investigates cell biology of kidney tissue development from stem cells, formation of epithelial tubules, and ex vivo nephrogenesis using progenitor niche signals. The institute's artificial intelligence capability centers on an in-house nnU-Net deep learning pipeline that performs automated segmentation and volumetric measurement of kidneys, liver, cysts, and spleen on MRI/CT abdominal scans, delivered through a web-based TraceOrg platform for monitoring autosomal dominant polycystic kidney disease (ADPKD) progression and treatment response, supplemented by multiparametric quantitative ultrasound and Mayo Imaging Classification scoring. Active clinical trials include the HemoCare Hemodialysis System home nocturnal study, the Tesevatinib ADPKD trial, the Water Therapy for ADPKD trial, and the CASCADE FH Registry.

The business model rests on three revenue streams: clinical care services reimbursed primarily through Medicare, Medicaid, and private insurance; clinical research revenue from pharmaceutical company trials, medical device studies, and federal/foundation grants; and charitable donations from individuals, foundations, and corporate donors supporting the not-for-profit mission. Go-to-market is sales-led, driven by direct physician referrals, self-referrals through the website appointment scheduler, and community engagement via the Wellness Program peer mentorship network. Strategic academic partnerships with NewYork-Presbyterian Hospital and Weill Cornell Medicine provide hospital privileges, training programs, and research collaboration, while a partnership with the National Kidney Foundation extends patient education reach.

Name

Rogosin Institute

Legal name

The Rogosin Institute

Website

https://rogosin.org

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

251–500 employees

Short description

The Rogosin Institute is a 501(c)(3) not-for-profit kidney care and research institution founded in 1983, operating as the largest US not-for-profit dialysis provider with 11 metropolitan centers. It delivers diagnosis, dialysis, transplant, specialty (PKD, lipid), and clinical research services to patients with chronic and end-stage kidney disease.

Ownership category

akta.pro rank

Product category

Nephrology and Kidney Disease Treatment Services

NAICS

Kidney Dialysis Centers (621492), Ambulatory Health Care Services (621)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Dialysis Services (Hemodialysis & Peritoneal Dialysis) (HLAKAHAC)

akta.pro secondary industries

Outpatient Dialysis & Kidney Care Centers (HLAFABAE), Genetic & Rare Kidney Disease Clinics (HLAKAHAO), General Nephrology Practice (HLAKAHAA), Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support) (HLALAFAC), Renal Transplant Medicine (Pre/Post-Transplant Care) (HLAKAHAD), Glomerular & Autoimmune Kidney Disease (Glomerulonephritis) Clinics (HLAKAHAG)

Keywords

• Kidney disease treatment
• Dialysis services
• Kidney transplant services
• Nephrology clinical research
• Home dialysis training

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Clinical Care Services: Revenue generated from providing kidney disease diagnosis, treatment, and management services including dialysis treatments, physician consultations, and transplant services. Services are primarily reimbursed through Medicare, Medicaid, and private insurance.
2. Clinical Research: Revenue from conducting clinical trials for pharmaceutical companies, medical device manufacturers, and research grants from federal agencies and foundations.
3. Donations: Charitable donations from individuals, foundations, and corporate donors supporting the not-for-profit mission. The organization is a registered 501(c)(3) with EIN 13-3184198.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

The Rogosin Institute provides comprehensive kidney disease care from diagnosis through transplant, operating eleven dialysis centers across the New York metropolitan area. Its core offerings include in-center hemodialysis, home hemodialysis, peritoneal dialysis (CAPD, CCPD), kidney transplantation with HLA typing and crossmatching, multidisciplinary PEAK late-stage CKD care, specialty centers for polycystic kidney disease and lipid control, and a clinical trials portfolio supported by a kidney regenerative medicine laboratory.

Product overview

Rogosin Institute is a not-for-profit healthcare organization (since 1983) specializing in kidney disease diagnostics, treatment, and management. The organization operates as a unified care ecosystem combining clinical services (dialysis, transplant, disease management), specialty centers (Polycystic Kidney Disease Center, Comprehensive Lipid Control Center), research programs (Clinical Trials, Kidney Regenerative Medicine Laboratory), and support programs (PEAK multidisciplinary care, Wellness Program). The core offerings include In-Center Hemodialysis, Home Hemodialysis, Peritoneal Dialysis, Kidney Transplant Services, and extensive clinical trials for novel therapies. With eleven dialysis centers, Rogosin is the largest not-for-profit kidney failure dialysis provider in the US.

Differentiator

Problem solved

Functional benefit

Products and services

• Dialysis Services

Quantifiable outcome

• 58% of PEAK program patients achieved optimal transition to ESKD vs 30% national average
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• National Kidney FoundationcoreStrategic or Co-development PartnerRogosin has a partnership with the National Kidney Foundation for patient education, including an educational page hosted on the NKF's learning center platform. The Wellness Program also directs patients to the National Kidney Foundation for additional educational resources.
• NewYork-Presbyterian HospitalcoreStrategic or Co-development PartnerRogosin physicians serve as attending physicians at NewYork-Presbyterian Hospital, and the organization collaborates with NYP on patient care, research, and training programs. Multiple physician profiles indicate dual appointments at Rogosin and NYP.
• Weill Cornell MedicinecoreStrategic or Co-development PartnerRogosin physicians hold academic appointments at Weill Cornell Medicine as professors, instructors, and attending physicians. The collaboration includes clinical care, research, and medical education. Multiple physician profiles confirm dual affiliations.
• Wellness Program AmbassadorsminorOthersThe Rogosin Wellness Program connects kidney patients to peer mentors living with kidney disease to empower patients to take charge of their healthcare decisions. This community-based partnership supports patient education and engagement.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Others

• National Kidney Foundation: NKF is a national patient-advocacy and education organization partnered with Rogosin through the learning center platform. Not a clinical peer, but adjacent as a kidney-focused non-profit that drives patient education, awareness, and referral flows relevant to Rogosin's mission.
• Weill Cornell Medicine: Weill Cornell is Rogosin's primary academic partner, employing its physicians as faculty and supporting joint research and training. Adjacent rather than a clinical peer, but materially comparable as an academic medical ecosystem that channels patient referrals and physician talent to Rogosin's centers.

Broad incumbents

• U.S. Renal Care: U.S. Renal Care is a for-profit dialysis provider operating hundreds of outpatient centers with a strong home dialysis program. Comparable as a multi-modality outpatient dialysis operator competing for the same patient population, but is private equity backed and multi-regional rather than concentrated in NY.
• Fresenius Medical Care: Fresenius Medical Care is the global leader in dialysis services and products, operating thousands of clinics worldwide alongside its equipment and dialyzer manufacturing. Comparable to Rogosin as a vertically integrated dialysis provider, but at vastly greater scale and with a for-profit, multi-national model.
• DaVita: DaVita is the largest U.S. for-profit dialysis provider with thousands of outpatient clinics delivering hemodialysis, peritoneal dialysis, and integrated kidney care. Directly comparable as a multi-center dialysis operator with home dialysis programs, but operates at national scale and is for-profit.
• American Renal Associates: American Renal Associates operates outpatient dialysis clinics across multiple U.S. states focused on in-center and home dialysis. Comparable as a multi-site outpatient dialysis operator, though for-profit and dissolved/acquired in 2021, making it a historical rather than active direct competitor.

Regional players

• NewYork-Presbyterian Hospital: NYP is a major academic medical center with which Rogosin physicians hold dual appointments and through which the institute runs in-hospital dialysis and transplant programs. Functionally a strategic partner as much as a peer, providing patient referrals, transplant infrastructure, and academic ties essential to Rogosin's clinical operations.

Direct peers

• Dialysis Clinic, Inc. (DCI): DCI is a national non-profit dialysis provider operating hundreds of clinics across the U.S. with a research/teaching mission. The closest peer to Rogosin by mission, non-profit status, integrated research arm, and multi-center outpatient dialysis model.
• Northwest Kidney Centers: Northwest Kidney Centers is one of the largest U.S. non-profit dialysis providers, focused on outpatient hemodialysis, home dialysis, and kidney disease education in the Pacific Northwest. Direct peer as a non-profit dialysis operator with a community service and research mission like Rogosin's.
• Satellite Healthcare: Satellite Healthcare is a non-profit dialysis organization focused on in-center and home dialysis along with patient-centered CKD research. Comparable to Rogosin in non-profit orientation, focus on home dialysis, and commitment to clinical research, though concentrated in California rather than New York.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@rogosininstitute
• Facebookfacebook.com/Rogosin
• Instagraminstagram.com/rogosininstitute
• Xx.com/rogosin

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rogosin Institute